Cite
Gerhard-Hartmann E, Goergen H, Bröckelmann PJ, et al. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. Br J Haematol. 2021;196(1):116-126doi: 10.1111/bjh.17793.
Gerhard-Hartmann, E., Goergen, H., Bröckelmann, P. J., Mottok, A., Steinmüller, T., Grund, J., Zamò, A., Ben-Neriah, S., Sasse, S., Borchmann, S., Fuchs, M., Borchmann, P., Reinke, S., Engert, A., Veldman, J., Diepstra, A., Klapper, W., & Rosenwald, A. (2022). 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. British journal of haematology, 196(1), 116-126. https://doi.org/10.1111/bjh.17793
Gerhard-Hartmann, Elena, et al. "9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial." British journal of haematology vol. 196,1 (2022): 116-126. doi: https://doi.org/10.1111/bjh.17793
Gerhard-Hartmann E, Goergen H, Bröckelmann PJ, Mottok A, Steinmüller T, Grund J, Zamò A, Ben-Neriah S, Sasse S, Borchmann S, Fuchs M, Borchmann P, Reinke S, Engert A, Veldman J, Diepstra A, Klapper W, Rosenwald A. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. Br J Haematol. 2022 Jan;196(1):116-126. doi: 10.1111/bjh.17793. Epub 2021 Sep 14. PMID: 34520052.
Copy
Download .nbib